<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301456</url>
  </required_header>
  <id_info>
    <org_study_id>B1111002</org_study_id>
    <nct_id>NCT01301456</nct_id>
  </id_info>
  <brief_title>Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of PF-04856883
      (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Findings</measure>
    <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
    <description>Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)</measure>
    <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
    <description>ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (&gt;=) 25 percent (%) increase when baseline greater than (&gt;)200 milliseconds (msec); or increase &gt;=50% when baseline less than or equal to (&lt;=200) msec; 2) QRS interval: &gt;=25% increase when baseline &gt;100 msec; &gt;=50% increase when baseline &lt;= 100 msec; 3) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) and Bazett's formula (QTcB interval): absolute value 450 - &lt;480 msec, 480 - &lt;500 msec &gt;=500; absolute change 30 - &lt;60, &gt;=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities</measure>
    <time_frame>Stage 1: Baseline up to Day 29; Stage 2 : Baseline up to Day 50</time_frame>
    <description>Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (&lt;) 40 beats per minute (bpm) or greater than (&gt;) 120 bpm, standing/supine systolic pulse &lt; 40 bpm or &gt; 140 bpm, systolic blood pressure of &gt;=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure &lt;90 mmHg, diastolic blood pressure &gt;=20 mmHg change from baseline and diastolic blood pressure &lt;50 mm Hg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements</measure>
    <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
    <description>Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) &lt;0.8*lower limit of the reference range (LLRR); leukocytes &lt;0.6*LLRR or &gt;1.5*ULRR; platelet count &lt;0.5*LLRR or &gt;1.75*upper limit of the reference range (ULRR); total neutrophils (absolute [abs]), lymphocytes (abs) &lt;0.8*LLRR or &gt;1.2*ULRR; eosinophils (abs), basophils (abs), monocytes (abs) &gt;1.2*ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin &gt;1.5*ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase &gt;3*ULRR, albumin, total protein &lt;0.8*LLRR or &gt;1.2*ULRR; blood urea nitrogen (BUN), creatinine &gt;1.3*ULRR; glucose (fasting) &lt;0.6*LLRR or &gt;1.5*ULRR; uric acid &gt;1.2* ULRR; sodium &lt;0.95*LLRR or &gt;1.05*ULRR; potassium, chloride, bicarbonate, calcium &lt;0.9*LLRR or &gt;1.1*ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =&gt;20/ high-power field (HPF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
    <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168 hours postdose Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168 hours postdose Day 22</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
    <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
    <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 2 only. Data was not estimable if values were below the limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1</measure>
    <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2</measure>
    <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</measure>
    <time_frame>Baseline, Day 3 and 8</time_frame>
    <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
    <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</measure>
    <time_frame>Baseline, Day 3 and 8</time_frame>
    <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
    <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</measure>
    <time_frame>Baseline, Day 3 and 8</time_frame>
    <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
    <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1</measure>
    <time_frame>Baseline, Day 2, 4, 6, 15, 22 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2</measure>
    <time_frame>Baseline, Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 29 and 50</time_frame>
    <description>HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1</measure>
    <time_frame>Baseline, Day 8, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 8, 15, 22, 29 and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1</measure>
    <time_frame>Baseline, Day 8, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2</measure>
    <time_frame>Baseline, Day 8, 15, 22, 29 and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADA): Stage 1</measure>
    <time_frame>Day 1 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Anti-Drug Antibodies (ADA): Stage 2</measure>
    <time_frame>Day 1, 29 and 50</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1 (Stage 1A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2 (Stage 1A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 3 (Stage 1A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 4 (Stage 1A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 5 (Stage 1B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 6 (Stage 1B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 7 (Stage 1B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 8 (Stage 1B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 9 (Stage 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 10 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 11 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 12 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 13 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single subcutaneous injection of placebo</description>
    <arm_group_label>Treatment Arm 1 (Stage 1A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 2 (Stage 1A)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 3 (Stage 1A)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 4 (Stage 1A)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single subcutaneous injection of placebo</description>
    <arm_group_label>Treatment Arm 5 (Stage 1B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 6 (Stage 1B)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 7 (Stage 1B)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Single subcutaneous injection of PF-04856883</description>
    <arm_group_label>Treatment Arm 8 (Stage 1B)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple weekly subcutaneous injections of placebo for 3 weeks</description>
    <arm_group_label>Treatment Arm 9 (Stage 2)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks</description>
    <arm_group_label>Treatment Arm 10 (Stage 2)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks</description>
    <arm_group_label>Treatment Arm 11 (Stage 2)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks</description>
    <arm_group_label>Treatment Arm 12 (Stage 2)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04856883</intervention_name>
    <description>Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks</description>
    <arm_group_label>Treatment Arm 13 (Stage 2)</arm_group_label>
    <other_name>CVX-096</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Type 2 diabetes and currently being treated with high dose metformin

          -  BMI between 22.0 and 40.0 kg/m2

          -  HbA1c between 7.0-10.0%

          -  Fasting C-peptide &gt;1.21 ng/mL

        Exclusion Criteria:

          -  History of clinically significant chronic conditions other than Type 2 diabetes not
             well controlled by either diet or medications

          -  Treatment with anti-diabetic therapies other than metformin

          -  History of allergic or anaphylactic reaction to any therapeutic or diagnostic
             monoclonal antibody

          -  Males or women of childbearing potential
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Clinical Pharmacology, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Discoveries LLC d/b/a ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1111002&amp;StudyName=Single-Dose%20And%20Multiple-Dose%20Safety%20And%20Tolerability%20Study%20Of%20PF-04856883%20In%20Type%202%20Diabetic%20Adult%20Females%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>July 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 9, 2018</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>CVX-096</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data for reporting arm Placebo 1a and 1b in stage 1 was planned to be pooled during analysis, as per protocol. Study consisted of two stages: stage 1 and stage 2. Participants were enrolled and randomized for stage 1 and stage 2 separately.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stage 1: PF-04856883 Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P2">
          <title>Stage 1: PF-04856883 4 mg</title>
          <description>Participants received PF-04856883 4 milligram (mg) subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P3">
          <title>Stage 1: PF-04856883 8 mg</title>
          <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P4">
          <title>Stage 1: PF-04856883 12 mg</title>
          <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P5">
          <title>Stage 1: PF-04856883 18 mg</title>
          <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P6">
          <title>Stage 1: PF-04856883 24 mg</title>
          <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P7">
          <title>Stage 1: PF-04856883 36 mg</title>
          <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="P8">
          <title>Stage 2: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="P9">
          <title>Stage 2: PF-04856883 12 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="P10">
          <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="P11">
          <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="P12">
          <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Stage 1: PF-04856883 Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B2">
          <title>Stage 1: PF-04856883 4 mg</title>
          <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B3">
          <title>Stage 1: PF-04856883 8 mg</title>
          <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B4">
          <title>Stage 1: PF-04856883 12 mg</title>
          <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B5">
          <title>Stage 1: PF-04856883 18 mg</title>
          <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B6">
          <title>Stage 1: PF-04856883 24 mg</title>
          <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B7">
          <title>Stage 1: PF-04856883 36 mg</title>
          <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="B8">
          <title>Stage 2: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="B9">
          <title>Stage 2: PF-04856883 12 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="B10">
          <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="B11">
          <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="B12">
          <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O11">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O12">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
        <description>Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.</description>
        <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36mg Single Dose</title>
            <description>Participants received subcutaneous injection of PF-04856883 4 mg by a 4-week follow up period in Stage 1</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O11">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O12">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
          <description>Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.</description>
          <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)</title>
        <description>ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (&gt;=) 25 percent (%) increase when baseline greater than (&gt;)200 milliseconds (msec); or increase &gt;=50% when baseline less than or equal to (&lt;=200) msec; 2) QRS interval: &gt;=25% increase when baseline &gt;100 msec; &gt;=50% increase when baseline &lt;= 100 msec; 3) QTCF interval: QTc interval using Fridericia’s formula (QTcF interval) and Bazett’s formula (QTcB interval): absolute value 450 - &lt;480 msec, 480 - &lt;500 msec &gt;=500; absolute change 30 - &lt;60, &gt;=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.</description>
        <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O11">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O12">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)</title>
          <description>ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (&gt;=) 25 percent (%) increase when baseline greater than (&gt;)200 milliseconds (msec); or increase &gt;=50% when baseline less than or equal to (&lt;=200) msec; 2) QRS interval: &gt;=25% increase when baseline &gt;100 msec; &gt;=50% increase when baseline &lt;= 100 msec; 3) QTCF interval: QTc interval using Fridericia’s formula (QTcF interval) and Bazett’s formula (QTcB interval): absolute value 450 - &lt;480 msec, 480 - &lt;500 msec &gt;=500; absolute change 30 - &lt;60, &gt;=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.</description>
          <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum PR Interval IFB: &gt;=25 or 50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcB Interval IFB: 30-&lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval IFB: 30-&lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Sign Abnormalities</title>
        <description>Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (&lt;) 40 beats per minute (bpm) or greater than (&gt;) 120 bpm, standing/supine systolic pulse &lt; 40 bpm or &gt; 140 bpm, systolic blood pressure of &gt;=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure &lt;90 mmHg, diastolic blood pressure &gt;=20 mmHg change from baseline and diastolic blood pressure &lt;50 mm Hg.</description>
        <time_frame>Stage 1: Baseline up to Day 29; Stage 2 : Baseline up to Day 50</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O11">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O12">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities</title>
          <description>Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (&lt;) 40 beats per minute (bpm) or greater than (&gt;) 120 bpm, standing/supine systolic pulse &lt; 40 bpm or &gt; 140 bpm, systolic blood pressure of &gt;=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure &lt;90 mmHg, diastolic blood pressure &gt;=20 mmHg change from baseline and diastolic blood pressure &lt;50 mm Hg.</description>
          <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements</title>
        <description>Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) &lt;0.8*lower limit of the reference range (LLRR); leukocytes &lt;0.6*LLRR or &gt;1.5*ULRR; platelet count &lt;0.5*LLRR or &gt;1.75*upper limit of the reference range (ULRR); total neutrophils (absolute [abs]), lymphocytes (abs) &lt;0.8*LLRR or &gt;1.2*ULRR; eosinophils (abs), basophils (abs), monocytes (abs) &gt;1.2*ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin &gt;1.5*ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase &gt;3*ULRR, albumin, total protein &lt;0.8*LLRR or &gt;1.2*ULRR; blood urea nitrogen (BUN), creatinine &gt;1.3*ULRR; glucose (fasting) &lt;0.6*LLRR or &gt;1.5*ULRR; uric acid &gt;1.2* ULRR; sodium &lt;0.95*LLRR or &gt;1.05*ULRR; potassium, chloride, bicarbonate, calcium &lt;0.9*LLRR or &gt;1.1*ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =&gt;20/ high-power field (HPF).</description>
        <time_frame>Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O8">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O9">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O10">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O11">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O12">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements</title>
          <description>Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) &lt;0.8*lower limit of the reference range (LLRR); leukocytes &lt;0.6*LLRR or &gt;1.5*ULRR; platelet count &lt;0.5*LLRR or &gt;1.75*upper limit of the reference range (ULRR); total neutrophils (absolute [abs]), lymphocytes (abs) &lt;0.8*LLRR or &gt;1.2*ULRR; eosinophils (abs), basophils (abs), monocytes (abs) &gt;1.2*ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin &gt;1.5*ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase &gt;3*ULRR, albumin, total protein &lt;0.8*LLRR or &gt;1.2*ULRR; blood urea nitrogen (BUN), creatinine &gt;1.3*ULRR; glucose (fasting) &lt;0.6*LLRR or &gt;1.5*ULRR; uric acid &gt;1.2* ULRR; sodium &lt;0.95*LLRR or &gt;1.05*ULRR; potassium, chloride, bicarbonate, calcium &lt;0.9*LLRR or &gt;1.1*ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =&gt;20/ high-power field (HPF).</description>
          <population>The safety population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1</title>
          <population>Pharmacokinetic (PK) parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.2" spread="85"/>
                    <measurement group_id="O2" value="324.7" spread="61"/>
                    <measurement group_id="O3" value="793.7" spread="65"/>
                    <measurement group_id="O4" value="1855" spread="66"/>
                    <measurement group_id="O5" value="1776" spread="21"/>
                    <measurement group_id="O6" value="2006" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1369" spread="17"/>
                    <measurement group_id="O2" value="1203" spread="20"/>
                    <measurement group_id="O3" value="1027" spread="29"/>
                    <measurement group_id="O4" value="1407" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n =5, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1802" spread="33"/>
                    <measurement group_id="O2" value="2757" spread="26"/>
                    <measurement group_id="O3" value="3030" spread="42"/>
                    <measurement group_id="O4" value="3046" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="72.0" upper_limit="336"/>
                    <measurement group_id="O2" value="120" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O3" value="120" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O4" value="120" lower_limit="48.0" upper_limit="120"/>
                    <measurement group_id="O5" value="120" lower_limit="72.0" upper_limit="168"/>
                    <measurement group_id="O6" value="122" lower_limit="120" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" lower_limit="336" upper_limit="336"/>
                    <measurement group_id="O2" value="336" lower_limit="335" upper_limit="336"/>
                    <measurement group_id="O3" value="335" lower_limit="24.1" upper_limit="336"/>
                    <measurement group_id="O4" value="336" lower_limit="336" upper_limit="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n =5, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="24.0" upper_limit="72.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="0.000" upper_limit="72.0"/>
                    <measurement group_id="O3" value="72.0" lower_limit="48.0" upper_limit="72.1"/>
                    <measurement group_id="O4" value="60.0" lower_limit="0.000" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1</title>
        <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1</title>
          <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44920" spread="112"/>
                    <measurement group_id="O2" value="95190" spread="76"/>
                    <measurement group_id="O3" value="295200" spread="46"/>
                    <measurement group_id="O4" value="527100" spread="53"/>
                    <measurement group_id="O5" value="711300" spread="13"/>
                    <measurement group_id="O6" value="652000" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2</title>
        <description>Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.</description>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168 hours postdose Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168 hours postdose Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2</title>
          <description>Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.</description>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85370" spread="38"/>
                    <measurement group_id="O2" value="99780" spread="41"/>
                    <measurement group_id="O3" value="89390" spread="35"/>
                    <measurement group_id="O4" value="91130" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n =5, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269000" spread="32"/>
                    <measurement group_id="O2" value="377400" spread="28"/>
                    <measurement group_id="O3" value="396300" spread="28"/>
                    <measurement group_id="O4" value="430500" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) of PF-04856883: Stage 1</title>
        <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.</description>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of PF-04856883: Stage 1</title>
          <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.</description>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>milliliter per hour (mL/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.14" spread="84"/>
                    <measurement group_id="O2" value="84.08" spread="59"/>
                    <measurement group_id="O3" value="40.60" spread="68"/>
                    <measurement group_id="O4" value="34.13" spread="35"/>
                    <measurement group_id="O5" value="33.73" spread="14"/>
                    <measurement group_id="O6" value="55.32" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) of PF-04856883: Stage 2</title>
        <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 2 only. Data was not estimable if values were below the limit of quantification.</description>
        <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of PF-04856883: Stage 2</title>
          <description>It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 2 only. Data was not estimable if values were below the limit of quantification.</description>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>mL/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.67" spread="28"/>
                    <measurement group_id="O2" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>milliliter (mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18760" spread="90"/>
                    <measurement group_id="O2" value="21710" spread="59"/>
                    <measurement group_id="O3" value="9191" spread="51"/>
                    <measurement group_id="O4" value="7127" spread="40"/>
                    <measurement group_id="O5" value="8437" spread="17"/>
                    <measurement group_id="O6" value="10010" spread="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2</title>
        <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9550" spread="29"/>
                    <measurement group_id="O2" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">Data was not estimable since values were below the limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1</title>
        <time_frame>predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.3" spread="13.614"/>
                    <measurement group_id="O2" value="179.7" spread="14.572"/>
                    <measurement group_id="O3" value="147.0" spread="18.520"/>
                    <measurement group_id="O4" value="133.8" spread="23.936"/>
                    <measurement group_id="O5" value="173.7" spread="7.0238"/>
                    <measurement group_id="O6" value="131.6" spread="45.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2</title>
        <time_frame>predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22</time_frame>
        <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2</title>
          <population>PK parameter analysis population included all randomized participants who had received at least one dose of study treatment and had at least 1 of the PK parameters of interest. Here, ‘N’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.4" spread="21.870"/>
                    <measurement group_id="O2" value="135.0" spread="43.980"/>
                    <measurement group_id="O3" value="143.8" spread="20.565"/>
                    <measurement group_id="O4" value="145.0" spread="37.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
        <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC</description>
        <time_frame>Baseline, Day 3 and 8</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
          <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>milligram*hour per deciliter (mg*hr/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656.35" spread="114.496"/>
                    <measurement group_id="O2" value="834.03" spread="158.952"/>
                    <measurement group_id="O3" value="712.11" spread="88.942"/>
                    <measurement group_id="O4" value="796.14" spread="208.733"/>
                    <measurement group_id="O5" value="660.64" spread="110.833"/>
                    <measurement group_id="O6" value="652.20" spread="48.707"/>
                    <measurement group_id="O7" value="636.57" spread="119.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" spread="89.366"/>
                    <measurement group_id="O2" value="77.82" spread="125.011"/>
                    <measurement group_id="O3" value="-89.38" spread="58.909"/>
                    <measurement group_id="O4" value="-101.47" spread="31.725"/>
                    <measurement group_id="O5" value="-68.05" spread="111.431"/>
                    <measurement group_id="O6" value="-141.27" spread="15.975"/>
                    <measurement group_id="O7" value="-153.04" spread="41.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =15, 5, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.82" spread="75.396"/>
                    <measurement group_id="O2" value="10.37" spread="158.368"/>
                    <measurement group_id="O3" value="0.85" spread="125.384"/>
                    <measurement group_id="O4" value="-82.51" spread="48.898"/>
                    <measurement group_id="O5" value="-28.36" spread="61.456"/>
                    <measurement group_id="O6" value="-123.43" spread="68.219"/>
                    <measurement group_id="O7" value="-39.60" spread="85.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
        <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
        <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
          <description>Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mg*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 4, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.49" spread="158.249"/>
                    <measurement group_id="O2" value="811.36" spread="131.145"/>
                    <measurement group_id="O3" value="756.17" spread="240.430"/>
                    <measurement group_id="O4" value="800.66" spread="206.776"/>
                    <measurement group_id="O5" value="723.57" spread="220.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =7, 4, 5, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.41" spread="74.405"/>
                    <measurement group_id="O2" value="-97.03" spread="55.692"/>
                    <measurement group_id="O3" value="-103.00" spread="118.759"/>
                    <measurement group_id="O4" value="-98.38" spread="114.644"/>
                    <measurement group_id="O5" value="-68.52" spread="153.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =7, 4, 6, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.48" spread="50.874"/>
                    <measurement group_id="O2" value="-265.64" spread="89.889"/>
                    <measurement group_id="O3" value="-293.04" spread="163.074"/>
                    <measurement group_id="O4" value="-254.54" spread="144.897"/>
                    <measurement group_id="O5" value="-240.65" spread="252.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 24 (n =7, 4, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="46.238"/>
                    <measurement group_id="O2" value="-146.61" spread="78.863"/>
                    <measurement group_id="O3" value="-207.12" spread="89.687"/>
                    <measurement group_id="O4" value="-242.35" spread="231.302"/>
                    <measurement group_id="O5" value="-121.13" spread="258.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =7, 4, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.08" spread="59.490"/>
                    <measurement group_id="O2" value="-55.43" spread="74.973"/>
                    <measurement group_id="O3" value="-157.54" spread="88.652"/>
                    <measurement group_id="O4" value="-192.97" spread="185.056"/>
                    <measurement group_id="O5" value="-106.58" spread="171.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n =7, 3, 6, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.26" spread="81.717"/>
                    <measurement group_id="O2" value="-48.82" spread="80.733"/>
                    <measurement group_id="O3" value="-33.77" spread="250.859"/>
                    <measurement group_id="O4" value="-125.06" spread="217.403"/>
                    <measurement group_id="O5" value="-23.99" spread="123.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
        <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
        <time_frame>Baseline, Day 3 and 8</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
          <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>milliUnit*hour per liter (mU*hr/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.18" spread="139.981"/>
                    <measurement group_id="O2" value="227.07" spread="142.547"/>
                    <measurement group_id="O3" value="210.80" spread="95.536"/>
                    <measurement group_id="O4" value="235.84" spread="130.071"/>
                    <measurement group_id="O5" value="105.34" spread="19.118"/>
                    <measurement group_id="O6" value="257.73" spread="127.358"/>
                    <measurement group_id="O7" value="283.59" spread="156.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.79" spread="115.555"/>
                    <measurement group_id="O2" value="22.99" spread="32.706"/>
                    <measurement group_id="O3" value="35.09" spread="57.093"/>
                    <measurement group_id="O4" value="12.15" spread="54.495"/>
                    <measurement group_id="O5" value="59.06" spread="94.643"/>
                    <measurement group_id="O6" value="83.82" spread="70.182"/>
                    <measurement group_id="O7" value="13.72" spread="98.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.23" spread="103.279"/>
                    <measurement group_id="O2" value="22.05" spread="89.419"/>
                    <measurement group_id="O3" value="39.96" spread="38.941"/>
                    <measurement group_id="O4" value="-50.51" spread="40.624"/>
                    <measurement group_id="O5" value="38.04" spread="15.736"/>
                    <measurement group_id="O6" value="-0.36" spread="50.674"/>
                    <measurement group_id="O7" value="1.08" spread="47.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
        <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
        <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
          <description>Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mU*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.26" spread="62.218"/>
                    <measurement group_id="O2" value="176.65" spread="76.040"/>
                    <measurement group_id="O3" value="267.29" spread="111.497"/>
                    <measurement group_id="O4" value="162.96" spread="111.688"/>
                    <measurement group_id="O5" value="190.64" spread="83.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.32" spread="62.135"/>
                    <measurement group_id="O2" value="13.29" spread="55.764"/>
                    <measurement group_id="O3" value="19.50" spread="134.651"/>
                    <measurement group_id="O4" value="27.99" spread="32.655"/>
                    <measurement group_id="O5" value="87.67" spread="124.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.77" spread="20.530"/>
                    <measurement group_id="O2" value="-39.16" spread="42.930"/>
                    <measurement group_id="O3" value="-10.07" spread="172.044"/>
                    <measurement group_id="O4" value="-51.69" spread="77.925"/>
                    <measurement group_id="O5" value="-24.36" spread="85.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 24 (n =7, 4, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="55.174"/>
                    <measurement group_id="O2" value="-15.19" spread="38.900"/>
                    <measurement group_id="O3" value="6.87" spread="184.830"/>
                    <measurement group_id="O4" value="4.18" spread="51.903"/>
                    <measurement group_id="O5" value="60.11" spread="189.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="55.799"/>
                    <measurement group_id="O2" value="3.98" spread="11.218"/>
                    <measurement group_id="O3" value="12.71" spread="115.095"/>
                    <measurement group_id="O4" value="-1.61" spread="85.866"/>
                    <measurement group_id="O5" value="15.70" spread="38.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" spread="29.909"/>
                    <measurement group_id="O2" value="-16.64" spread="33.133"/>
                    <measurement group_id="O3" value="-57.14" spread="116.193"/>
                    <measurement group_id="O4" value="49.27" spread="81.874"/>
                    <measurement group_id="O5" value="-26.78" spread="81.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
        <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
        <time_frame>Baseline, Day 3 and 8</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1</title>
          <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7,5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" spread="5.332"/>
                    <measurement group_id="O2" value="16.63" spread="7.743"/>
                    <measurement group_id="O3" value="16.43" spread="4.306"/>
                    <measurement group_id="O4" value="16.80" spread="5.711"/>
                    <measurement group_id="O5" value="10.64" spread="1.156"/>
                    <measurement group_id="O6" value="16.17" spread="4.531"/>
                    <measurement group_id="O7" value="18.37" spread="7.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =15, 5, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="3.653"/>
                    <measurement group_id="O2" value="0.69" spread="1.465"/>
                    <measurement group_id="O3" value="1.65" spread="4.958"/>
                    <measurement group_id="O4" value="1.05" spread="1.885"/>
                    <measurement group_id="O5" value="4.30" spread="4.102"/>
                    <measurement group_id="O6" value="5.34" spread="2.584"/>
                    <measurement group_id="O7" value="2.34" spread="4.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =15, 4, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="2.864"/>
                    <measurement group_id="O2" value="1.06" spread="1.806"/>
                    <measurement group_id="O3" value="0.83" spread="1.651"/>
                    <measurement group_id="O4" value="-2.74" spread="1.380"/>
                    <measurement group_id="O5" value="1.70" spread="1.544"/>
                    <measurement group_id="O6" value="-0.45" spread="2.883"/>
                    <measurement group_id="O7" value="-0.38" spread="1.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
        <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
        <time_frame>Baseline, Day 3, 15, 24, 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2</title>
          <description>Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47" spread="4.315"/>
                    <measurement group_id="O2" value="14.59" spread="4.205"/>
                    <measurement group_id="O3" value="15.63" spread="4.293"/>
                    <measurement group_id="O4" value="11.74" spread="5.210"/>
                    <measurement group_id="O5" value="14.14" spread="5.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="2.182"/>
                    <measurement group_id="O2" value="1.89" spread="4.705"/>
                    <measurement group_id="O3" value="0.50" spread="4.757"/>
                    <measurement group_id="O4" value="3.16" spread="1.613"/>
                    <measurement group_id="O5" value="3.49" spread="4.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.493"/>
                    <measurement group_id="O2" value="-1.55" spread="2.821"/>
                    <measurement group_id="O3" value="-1.92" spread="6.930"/>
                    <measurement group_id="O4" value="-0.17" spread="4.135"/>
                    <measurement group_id="O5" value="-0.50" spread="4.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 24 (n =7, 4, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="3.518"/>
                    <measurement group_id="O2" value="0.71" spread="4.312"/>
                    <measurement group_id="O3" value="-0.99" spread="6.220"/>
                    <measurement group_id="O4" value="1.63" spread="2.994"/>
                    <measurement group_id="O5" value="1.21" spread="5.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="3.864"/>
                    <measurement group_id="O2" value="-0.07" spread="2.545"/>
                    <measurement group_id="O3" value="-0.59" spread="4.144"/>
                    <measurement group_id="O4" value="0.59" spread="2.733"/>
                    <measurement group_id="O5" value="0.41" spread="2.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.978"/>
                    <measurement group_id="O2" value="-1.83" spread="2.015"/>
                    <measurement group_id="O3" value="-4.10" spread="5.265"/>
                    <measurement group_id="O4" value="1.06" spread="1.474"/>
                    <measurement group_id="O5" value="-2.90" spread="3.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1</title>
        <time_frame>Baseline, Day 2, 4, 6, 15, 22 and 29</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 2: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.67" spread="27.102"/>
                    <measurement group_id="O2" value="219.60" spread="44.557"/>
                    <measurement group_id="O3" value="171.17" spread="23.752"/>
                    <measurement group_id="O4" value="174.00" spread="48.949"/>
                    <measurement group_id="O5" value="168.57" spread="38.336"/>
                    <measurement group_id="O6" value="145.60" spread="21.606"/>
                    <measurement group_id="O7" value="158.14" spread="35.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="11.807"/>
                    <measurement group_id="O2" value="13.60" spread="32.393"/>
                    <measurement group_id="O3" value="-18.67" spread="21.011"/>
                    <measurement group_id="O4" value="-20.50" spread="20.433"/>
                    <measurement group_id="O5" value="-22.14" spread="34.090"/>
                    <measurement group_id="O6" value="-35.00" spread="12.369"/>
                    <measurement group_id="O7" value="-29.71" spread="30.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =15, 5, 5, 6, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="17.161"/>
                    <measurement group_id="O2" value="19.60" spread="35.683"/>
                    <measurement group_id="O3" value="-12.40" spread="17.358"/>
                    <measurement group_id="O4" value="-10.33" spread="15.744"/>
                    <measurement group_id="O5" value="-30.71" spread="13.841"/>
                    <measurement group_id="O6" value="-27.00" spread="8.803"/>
                    <measurement group_id="O7" value="-28.33" spread="21.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n =15, 5, 4, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.80" spread="29.547"/>
                    <measurement group_id="O2" value="26.40" spread="32.377"/>
                    <measurement group_id="O3" value="10.25" spread="29.056"/>
                    <measurement group_id="O4" value="-8.33" spread="27.156"/>
                    <measurement group_id="O5" value="-6.29" spread="15.850"/>
                    <measurement group_id="O6" value="-16.80" spread="19.176"/>
                    <measurement group_id="O7" value="-16.14" spread="22.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.13" spread="32.822"/>
                    <measurement group_id="O2" value="-13.80" spread="46.949"/>
                    <measurement group_id="O3" value="23.80" spread="56.857"/>
                    <measurement group_id="O4" value="19.33" spread="16.476"/>
                    <measurement group_id="O5" value="8.00" spread="21.223"/>
                    <measurement group_id="O6" value="3.40" spread="27.309"/>
                    <measurement group_id="O7" value="-2.71" spread="16.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 22 (n =14, 4, 5, 6, 6, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="28.205"/>
                    <measurement group_id="O2" value="23.75" spread="61.163"/>
                    <measurement group_id="O3" value="33.40" spread="76.064"/>
                    <measurement group_id="O4" value="11.17" spread="26.446"/>
                    <measurement group_id="O5" value="2.17" spread="15.065"/>
                    <measurement group_id="O6" value="1.20" spread="18.847"/>
                    <measurement group_id="O7" value="-0.57" spread="13.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =14, 5, 5, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.00" spread="33.439"/>
                    <measurement group_id="O2" value="1.60" spread="27.763"/>
                    <measurement group_id="O3" value="27.80" spread="29.575"/>
                    <measurement group_id="O4" value="0.33" spread="16.978"/>
                    <measurement group_id="O5" value="1.57" spread="21.220"/>
                    <measurement group_id="O6" value="-3.80" spread="22.643"/>
                    <measurement group_id="O7" value="-2.29" spread="19.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2</title>
        <time_frame>Baseline, Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.00" spread="33.317"/>
                    <measurement group_id="O2" value="186.80" spread="23.059"/>
                    <measurement group_id="O3" value="191.14" spread="56.153"/>
                    <measurement group_id="O4" value="187.29" spread="45.756"/>
                    <measurement group_id="O5" value="158.50" spread="18.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n =5, 4, 7, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="15.281"/>
                    <measurement group_id="O2" value="-26.75" spread="15.108"/>
                    <measurement group_id="O3" value="-15.14" spread="21.217"/>
                    <measurement group_id="O4" value="-23.43" spread="35.142"/>
                    <measurement group_id="O5" value="-10.40" spread="18.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n =5, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.60" spread="6.427"/>
                    <measurement group_id="O2" value="-14.80" spread="24.284"/>
                    <measurement group_id="O3" value="-14.86" spread="48.657"/>
                    <measurement group_id="O4" value="-20.33" spread="22.818"/>
                    <measurement group_id="O5" value="-1.50" spread="27.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n =7, 4, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="40.240"/>
                    <measurement group_id="O2" value="5.75" spread="14.080"/>
                    <measurement group_id="O3" value="-44.86" spread="38.451"/>
                    <measurement group_id="O4" value="-8.00" spread="42.942"/>
                    <measurement group_id="O5" value="-15.83" spread="8.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =6, 5, 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="17.627"/>
                    <measurement group_id="O2" value="4.20" spread="19.967"/>
                    <measurement group_id="O3" value="-37.43" spread="42.383"/>
                    <measurement group_id="O4" value="2.60" spread="73.449"/>
                    <measurement group_id="O5" value="24.50" spread="47.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 22 (n =7, 4, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="15.294"/>
                    <measurement group_id="O2" value="-4.25" spread="13.817"/>
                    <measurement group_id="O3" value="-39.57" spread="25.468"/>
                    <measurement group_id="O4" value="-14.17" spread="38.270"/>
                    <measurement group_id="O5" value="-0.33" spread="51.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 23 (n =7, 4, 6, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.71" spread="23.894"/>
                    <measurement group_id="O2" value="-27.25" spread="27.293"/>
                    <measurement group_id="O3" value="-40.33" spread="18.327"/>
                    <measurement group_id="O4" value="-17.50" spread="73.519"/>
                    <measurement group_id="O5" value="-24.00" spread="29.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 25 (n =7, 5, 6, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.43" spread="13.113"/>
                    <measurement group_id="O2" value="-16.60" spread="43.443"/>
                    <measurement group_id="O3" value="-44.67" spread="27.667"/>
                    <measurement group_id="O4" value="-23.33" spread="52.936"/>
                    <measurement group_id="O5" value="-16.20" spread="36.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 27 (n =7, 5, 6, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="21.110"/>
                    <measurement group_id="O2" value="-21.60" spread="15.821"/>
                    <measurement group_id="O3" value="-37.33" spread="17.963"/>
                    <measurement group_id="O4" value="-34.67" spread="35.803"/>
                    <measurement group_id="O5" value="12.00" spread="71.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 30 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="12.739"/>
                    <measurement group_id="O2" value="-14.20" spread="17.908"/>
                    <measurement group_id="O3" value="-22.29" spread="26.171"/>
                    <measurement group_id="O4" value="-9.33" spread="32.898"/>
                    <measurement group_id="O5" value="15.40" spread="37.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 36 (n =6, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.50" spread="32.415"/>
                    <measurement group_id="O2" value="0.40" spread="37.846"/>
                    <measurement group_id="O3" value="1.86" spread="25.373"/>
                    <measurement group_id="O4" value="-5.83" spread="32.009"/>
                    <measurement group_id="O5" value="27.67" spread="59.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 43 (n =7, 5, 5, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.71" spread="22.552"/>
                    <measurement group_id="O2" value="12.80" spread="29.064"/>
                    <measurement group_id="O3" value="13.20" spread="17.254"/>
                    <measurement group_id="O4" value="-1.17" spread="41.787"/>
                    <measurement group_id="O5" value="8.33" spread="18.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2</title>
        <description>A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.</description>
        <time_frame>Baseline, Day 30</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2</title>
          <description>A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7 ,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.19" spread="35.437"/>
                    <measurement group_id="O2" value="212.43" spread="52.764"/>
                    <measurement group_id="O3" value="205.56" spread="51.907"/>
                    <measurement group_id="O4" value="202.43" spread="38.900"/>
                    <measurement group_id="O5" value="186.13" spread="33.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 30 (n =7, 5, 7, 6 ,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.36" spread="38.825"/>
                    <measurement group_id="O2" value="191.20" spread="43.953"/>
                    <measurement group_id="O3" value="172.24" spread="48.067"/>
                    <measurement group_id="O4" value="174.08" spread="41.437"/>
                    <measurement group_id="O5" value="192.87" spread="58.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.219</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>Least square (LS) mean</param_type>
            <param_value>-21.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.766</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.26</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean</param_type>
            <param_value>-34.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.189</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.20</ci_lower_limit>
            <ci_upper_limit>-14.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean</param_type>
            <param_value>-33.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.806</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.50</ci_lower_limit>
            <ci_upper_limit>-12.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.857</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean</param_type>
            <param_value>-2.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.111</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.16</ci_lower_limit>
            <ci_upper_limit>18.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2</title>
        <description>HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.</description>
        <time_frame>Baseline, Day 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2</title>
          <description>HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.</description>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.547"/>
                    <measurement group_id="O2" value="-0.24" spread="0.288"/>
                    <measurement group_id="O3" value="-0.41" spread="0.212"/>
                    <measurement group_id="O4" value="-0.42" spread="0.440"/>
                    <measurement group_id="O5" value="-0.40" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (n =6, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.769"/>
                    <measurement group_id="O2" value="-0.08" spread="0.335"/>
                    <measurement group_id="O3" value="-0.24" spread="0.326"/>
                    <measurement group_id="O4" value="-0.33" spread="0.754"/>
                    <measurement group_id="O5" value="-0.40" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.419</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.251</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.224</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.230</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.244</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1</title>
        <time_frame>Baseline, Day 8, 15 and 29</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>micromole per liter (mcmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.60" spread="34.618"/>
                    <measurement group_id="O2" value="289.20" spread="48.329"/>
                    <measurement group_id="O3" value="279.67" spread="30.507"/>
                    <measurement group_id="O4" value="304.83" spread="45.155"/>
                    <measurement group_id="O5" value="263.43" spread="34.942"/>
                    <measurement group_id="O6" value="259.80" spread="53.644"/>
                    <measurement group_id="O7" value="273.71" spread="36.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="14.461"/>
                    <measurement group_id="O2" value="20.20" spread="10.986"/>
                    <measurement group_id="O3" value="4.20" spread="18.295"/>
                    <measurement group_id="O4" value="5.67" spread="13.095"/>
                    <measurement group_id="O5" value="4.29" spread="16.720"/>
                    <measurement group_id="O6" value="-13.60" spread="23.554"/>
                    <measurement group_id="O7" value="-12.29" spread="10.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.67" spread="17.839"/>
                    <measurement group_id="O2" value="-20.40" spread="25.393"/>
                    <measurement group_id="O3" value="-16.40" spread="13.502"/>
                    <measurement group_id="O4" value="-9.17" spread="25.135"/>
                    <measurement group_id="O5" value="13.33" spread="24.188"/>
                    <measurement group_id="O6" value="-9.60" spread="22.267"/>
                    <measurement group_id="O7" value="-3.00" spread="11.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="19.627"/>
                    <measurement group_id="O2" value="8.40" spread="30.876"/>
                    <measurement group_id="O3" value="7.20" spread="29.660"/>
                    <measurement group_id="O4" value="-4.50" spread="16.109"/>
                    <measurement group_id="O5" value="15.86" spread="24.024"/>
                    <measurement group_id="O6" value="1.40" spread="17.344"/>
                    <measurement group_id="O7" value="-4.43" spread="18.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2</title>
        <time_frame>Baseline, Day 8, 15, 22, 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mcmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.14" spread="57.875"/>
                    <measurement group_id="O2" value="309.40" spread="47.600"/>
                    <measurement group_id="O3" value="301.14" spread="43.690"/>
                    <measurement group_id="O4" value="291.29" spread="37.911"/>
                    <measurement group_id="O5" value="303.67" spread="47.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.29" spread="19.678"/>
                    <measurement group_id="O2" value="-8.20" spread="11.100"/>
                    <measurement group_id="O3" value="-12.14" spread="12.668"/>
                    <measurement group_id="O4" value="-9.17" spread="23.043"/>
                    <measurement group_id="O5" value="-10.17" spread="21.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="21.146"/>
                    <measurement group_id="O2" value="-8.20" spread="15.707"/>
                    <measurement group_id="O3" value="-39.29" spread="21.077"/>
                    <measurement group_id="O4" value="-11.67" spread="24.047"/>
                    <measurement group_id="O5" value="-14.67" spread="33.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 22 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="13.176"/>
                    <measurement group_id="O2" value="-18.20" spread="20.462"/>
                    <measurement group_id="O3" value="-37.86" spread="19.945"/>
                    <measurement group_id="O4" value="-24.67" spread="20.925"/>
                    <measurement group_id="O5" value="-27.50" spread="25.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =7, 5, 7, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="27.098"/>
                    <measurement group_id="O2" value="-26.60" spread="22.612"/>
                    <measurement group_id="O3" value="-37.57" spread="14.976"/>
                    <measurement group_id="O4" value="-32.67" spread="28.507"/>
                    <measurement group_id="O5" value="-41.00" spread="29.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.86" spread="20.732"/>
                    <measurement group_id="O2" value="-8.80" spread="14.446"/>
                    <measurement group_id="O3" value="-6.43" spread="20.871"/>
                    <measurement group_id="O4" value="-12.43" spread="26.732"/>
                    <measurement group_id="O5" value="-5.67" spread="31.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.326</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.16</ci_lower_limit>
            <ci_upper_limit>16.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <method>mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.472</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.03</ci_lower_limit>
            <ci_upper_limit>9.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.791</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.20</ci_lower_limit>
            <ci_upper_limit>12.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.936</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.829</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.89</ci_lower_limit>
            <ci_upper_limit>12.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.037</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.46</ci_lower_limit>
            <ci_upper_limit>17.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-32.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.872</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.07</ci_lower_limit>
            <ci_upper_limit>-16.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.833</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.212</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.67</ci_lower_limit>
            <ci_upper_limit>13.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.365</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.47</ci_lower_limit>
            <ci_upper_limit>9.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.703</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.713</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.52</ci_lower_limit>
            <ci_upper_limit>9.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-25.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.827</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.07</ci_lower_limit>
            <ci_upper_limit>-13.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.061</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.51</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.198</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.57</ci_lower_limit>
            <ci_upper_limit>-2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.421</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.17</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-28.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.393</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.84</ci_lower_limit>
            <ci_upper_limit>-14.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-22.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.773</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.65</ci_lower_limit>
            <ci_upper_limit>-8.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-28.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.837</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.19</ci_lower_limit>
            <ci_upper_limit>-13.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.576</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.77</ci_lower_limit>
            <ci_upper_limit>22.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.666</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.365</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.86</ci_lower_limit>
            <ci_upper_limit>21.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.333</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.27</ci_lower_limit>
            <ci_upper_limit>13.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.877</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.15</ci_lower_limit>
            <ci_upper_limit>23.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1</title>
        <time_frame>Baseline, Day 8, 15 and 29</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O7">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =15, 5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="5.021"/>
                    <measurement group_id="O2" value="5.02" spread="2.831"/>
                    <measurement group_id="O3" value="5.77" spread="1.306"/>
                    <measurement group_id="O4" value="5.35" spread="3.683"/>
                    <measurement group_id="O5" value="6.20" spread="5.440"/>
                    <measurement group_id="O6" value="12.04" spread="5.133"/>
                    <measurement group_id="O7" value="11.84" spread="8.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =15, 5, 5, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.895"/>
                    <measurement group_id="O2" value="-0.36" spread="0.727"/>
                    <measurement group_id="O3" value="0.64" spread="0.639"/>
                    <measurement group_id="O4" value="0.15" spread="0.596"/>
                    <measurement group_id="O5" value="0.73" spread="0.632"/>
                    <measurement group_id="O6" value="0.00" spread="1.584"/>
                    <measurement group_id="O7" value="0.97" spread="0.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =15, 5, 5, 6, 6, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.047"/>
                    <measurement group_id="O2" value="0.42" spread="1.711"/>
                    <measurement group_id="O3" value="1.50" spread="1.321"/>
                    <measurement group_id="O4" value="-0.32" spread="1.143"/>
                    <measurement group_id="O5" value="1.07" spread="1.111"/>
                    <measurement group_id="O6" value="0.32" spread="1.608"/>
                    <measurement group_id="O7" value="1.17" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =15, 5, 5, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.608"/>
                    <measurement group_id="O2" value="-0.36" spread="0.820"/>
                    <measurement group_id="O3" value="-0.52" spread="3.192"/>
                    <measurement group_id="O4" value="-0.62" spread="1.492"/>
                    <measurement group_id="O5" value="0.97" spread="1.467"/>
                    <measurement group_id="O6" value="0.36" spread="1.499"/>
                    <measurement group_id="O7" value="0.66" spread="1.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2</title>
        <time_frame>Baseline, Day 8, 15, 22, 29 and 50</time_frame>
        <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O5">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2</title>
          <population>Pharmacodynamic analysis population included all enrolled participants who had received at least 1 dose of study treatment and have at least 1 pharmacodynamic parameter. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread="4.351"/>
                    <measurement group_id="O2" value="6.32" spread="3.517"/>
                    <measurement group_id="O3" value="8.09" spread="6.240"/>
                    <measurement group_id="O4" value="7.59" spread="5.538"/>
                    <measurement group_id="O5" value="3.95" spread="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.663"/>
                    <measurement group_id="O2" value="0.40" spread="0.962"/>
                    <measurement group_id="O3" value="0.41" spread="0.570"/>
                    <measurement group_id="O4" value="-0.08" spread="1.599"/>
                    <measurement group_id="O5" value="0.90" spread="0.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.376"/>
                    <measurement group_id="O2" value="0.72" spread="1.512"/>
                    <measurement group_id="O3" value="1.21" spread="0.641"/>
                    <measurement group_id="O4" value="0.32" spread="2.483"/>
                    <measurement group_id="O5" value="0.63" spread="1.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 22 (n =7, 5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="1.289"/>
                    <measurement group_id="O2" value="1.14" spread="0.518"/>
                    <measurement group_id="O3" value="1.73" spread="1.034"/>
                    <measurement group_id="O4" value="0.95" spread="3.086"/>
                    <measurement group_id="O5" value="1.28" spread="2.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 (n =7, 5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="1.765"/>
                    <measurement group_id="O2" value="1.46" spread="0.730"/>
                    <measurement group_id="O3" value="1.83" spread="1.241"/>
                    <measurement group_id="O4" value="1.50" spread="2.900"/>
                    <measurement group_id="O5" value="1.60" spread="2.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 50 (n =7, 5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="2.106"/>
                    <measurement group_id="O2" value="0.38" spread="2.381"/>
                    <measurement group_id="O3" value="-0.30" spread="1.294"/>
                    <measurement group_id="O4" value="1.64" spread="2.985"/>
                    <measurement group_id="O5" value="0.92" spread="2.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.387</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.551</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.309</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.501</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.518</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 8: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.542</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.434</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.923</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.150</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.841</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.861</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 15: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.492</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.888</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.064</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean Difference</param_type>
            <param_value>1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.970</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.461</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean Difference</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.993</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 22: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS mean Difference</param_type>
            <param_value>1.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.021</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.172</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.069</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.092</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 29: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.129</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.317</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.568</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.201</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.201</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 50: Repeated measures analysis of change is performed with change from baseline as dependent variable, treatment as a factor and baseline as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.710</p_value>
            <method>Mixed meal tolerance test</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.260</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug Antibodies (ADA): Stage 1</title>
        <time_frame>Day 1 and 29</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: PF-04856883 4 mg</title>
            <description>Participants received PF-04856883 4 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: PF-04856883 8 mg</title>
            <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: PF-04856883 12 mg</title>
            <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: PF-04856883 18 mg</title>
            <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O5">
            <title>Stage 1: PF-04856883 24 mg</title>
            <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
          <group group_id="O6">
            <title>Stage 1: PF-04856883 36 mg</title>
            <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibodies (ADA): Stage 1</title>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =5, 6, 6, 7, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n =5, 5, 6, 6, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Anti-Drug Antibodies (ADA): Stage 2</title>
        <time_frame>Day 1, 29 and 50</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: PF-04856883 12 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
            <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
          <group group_id="O4">
            <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
            <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Anti-Drug Antibodies (ADA): Stage 2</title>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘n’ signifies those participants who were evaluable at specified time point for each arm, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =5, 7, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n =5, 7, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (n =5, 7, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stage 1: PF-04856883 Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneously injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E2">
          <title>Stage 1: PF-04856883 4 mg</title>
          <description>Participants received PF-04856883 4 milligram (mg) subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E3">
          <title>Stage 1: PF-04856883 8 mg</title>
          <description>Participants received PF-04856883 8 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E4">
          <title>Stage 1: PF-04856883 12 mg</title>
          <description>Participants received PF-04856883 12 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E5">
          <title>Stage 1: PF-04856883 18 mg</title>
          <description>Participants received PF-04856883 18 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E6">
          <title>Stage 1: PF-04856883 24 mg</title>
          <description>Participants received PF-04856883 24 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E7">
          <title>Stage 1: PF-04856883 36 mg</title>
          <description>Participants received PF-04856883 36 mg subcutaneous injection once on Day 1 in Stage 1.</description>
        </group>
        <group group_id="E8">
          <title>Stage 2: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="E9">
          <title>Stage 2: PF-04856883 12.0 mg</title>
          <description>Participants received single dose of PF-04856883 12.0 mg subcutaneous injection on Day 1, 8, 15 and 22 in Stage 2.</description>
        </group>
        <group group_id="E10">
          <title>Stage 2: PF-04856883 12 mg + 12 mg + 24 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 12 mg, 24 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="E11">
          <title>Stage 2: PF-04856883 8 mg + 8 mg + 16 mg + 24 mg</title>
          <description>Participants received single dose of PF-04856883 8 mg, 8 mg, 16 mg, 24 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
        <group group_id="E12">
          <title>Stage 2: PF-04856883 12 mg + 20 mg + 28 mg + 36 mg</title>
          <description>Participants received single dose of PF-04856883 12 mg, 20 mg, 28 mg, 36 mg subcutaneous injection on Day 1, 8, 15 and 22 respectively in Stage 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Faecal volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

